Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Augusta University
European Organisation for Research and Treatment of Cancer - EORTC
The University of Texas Health Science Center at San Antonio
Duke University
Philogen S.p.A.
Istari Oncology, Inc.
CNS Pharmaceuticals, Inc.
Philogen S.p.A.
Actuate Therapeutics Inc.
Refnot-Pharm Ltd
Children's Oncology Group
AIDS Malignancy Consortium
Istituto Oncologico Veneto IRCCS
AbbVie
M.D. Anderson Cancer Center
Universitair Ziekenhuis Brussel
Hoffmann-La Roche
OHSU Knight Cancer Institute
Alliance for Clinical Trials in Oncology
Isarna Therapeutics GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Incheon St.Mary's Hospital
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
University Hospital Freiburg